<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00326456</url>
  </required_header>
  <id_info>
    <org_study_id>MITO-2</org_study_id>
    <secondary_id>2005-004453-98</secondary_id>
    <nct_id>NCT00326456</nct_id>
  </id_info>
  <brief_title>MITO-2: A Study Comparing 2 Chemotherapy Regimens (Carboplatin/Liposomal Doxorubicin vs Carboplatin/Paclitaxel) in Patients With Ovarian Cancer</brief_title>
  <official_title>Phase III Randomized Multicentre Trial of Carboplatin + Liposomal Doxorubicin vs Carboplatin + Paclitaxel in Patients With Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute, Naples</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute, Naples</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the effectiveness (progression free survival) of the
      experimental combination of carboplatin + liposomal doxorubicin with the standard combination
      of carboplatin + paclitaxel in first line treatment of patients with ovarian cancer.

      Secondary objectives are to evaluate overall survival, quality of life, objective response
      rate, and toxicity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ovarian cancer is the second most frequent and the most deadly gynaecologic cancer. The high
      mortality rate is due to the late diagnosis of this malignancy that often develops without
      symptoms, as well as to limited results in treatment of the disease. Patients may respond
      well initially to chemotherapy, but the vast majority of patients will experience a
      progression of the disease. The poor long term results in the standard treatment available
      today for first-line chemotherapy of ovarian cancer make research into new, more beneficial
      treatment strategies necessary. The proven efficacy of liposomal doxorubicin in second line
      treatment, where it is the first drug to have shown some significant benefit in terms of
      survival, and the possibility of easily combining it with full doses and normal use of
      carboplatin, encourages the testing of the effectiveness of the combination of carboplatin
      and liposomal doxorubicin in first line treatment.

      Patients enrolled into this study will be randomly assigned to one of two treatment groups:

      · Standard therapy consisting of 6 cycles of chemotherapy:

        -  carboplatin AUC 5 given intravenously on day 1 every 3 weeks AND

        -  paclitaxel 175 mg/m2 given intravenously on day 1 every 3 weeks

      OR

      · Experimental therapy consisting of 6 cycles of chemotherapy:

        -  carboplatin AUC 5 given intravenously on day 1 every 3 weeks AND

        -  liposomal doxorubicin 30 mg/m2 given intravenously on day 1 every 3 weeks
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2003</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>at 2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life</measure>
    <time_frame>at baseline and every 3 weeks during treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>objective response rate</measure>
    <time_frame>at 9 and 18 weeks after starting study therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>toxicity</measure>
    <time_frame>every 3 weeks during chemotherapy</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">820</enrollment>
  <condition>Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>carboplatin and liposomal doxorubicin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>carboplatin and paclitaxel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>liposomal doxorubicin</intervention_name>
    <description>30 mg/m2 gieven intravenously on day 1 every 3 weeks</description>
    <arm_group_label>carboplatin and liposomal doxorubicin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
    <description>AUC 5 intravenously on day 1 every 3 weeks</description>
    <arm_group_label>carboplatin and liposomal doxorubicin</arm_group_label>
    <arm_group_label>carboplatin and paclitaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
    <description>175 mg/m2 intravenously on day 1 every 3 weeks</description>
    <arm_group_label>carboplatin and paclitaxel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cytologic / histologic diagnosis of stage Ic-IV ovarian cancer

          -  Indication for chemotherapy treatment

          -  Age 75 years or less

          -  Life expectancy of at least 3 months

        Exclusion Criteria:

          -  Previous or concomitant malignant neoplasia (not including basocellular or
             spinocellular skin carcinoma or in-situ carcinoma of the uterine cervix, provided they
             are being adequately treated)

          -  Performance status (ECOG) &gt; 2

          -  Previous chemotherapy treatment

          -  Heart disease (heart failure, myocardial heart attack within 6 months prior to
             randomization, atrioventricular block of any degree, serious arrhythmia)

          -  Leukocytes &lt; 4000/mm3, neutrophils &lt; 2000/mm3, platelets &lt; 100000/mm3

          -  Impaired renal function (creatinine &gt; 1.25 times the upper normal limit) or liver
             function (SGOT or SGPT &gt; 1.25 times the upper normal limit)

          -  Present or suspected hemorrhagic syndromes

          -  Uncooperative and/or unreliable patients

          -  Patient's inability to access the center

          -  Refusal of informed consent
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sandro Pignata, M.D., Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute, Naples</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francesco Perrone, M.D., Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute, Naples</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinica Malzoni, Reparto di Ginecologia Oncologica</name>
      <address>
        <city>Avellino</city>
        <state>AV</state>
        <zip>83100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera S. Giuseppe Moscati, U.O. di Oncologia Medica</name>
      <address>
        <city>Monteforte Irpino</city>
        <state>AV</state>
        <zip>83024</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Regionale Miulli, Divisione Medicina Interna Sezione Oncologica</name>
      <address>
        <city>Acquaviva delle Fonti</city>
        <state>BA</state>
        <zip>70021</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Oncologico Bari, Oncologia Medica</name>
      <address>
        <city>Bari</city>
        <state>BA</state>
        <zip>70126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Oncologico di Bari, U.O. di Oncologia Medica e Sperimentale</name>
      <address>
        <city>Bari</city>
        <state>BA</state>
        <zip>70126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Riuniti di Bergamo, U.O. di Ostetricia e Ginecologia</name>
      <address>
        <city>Bergamo</city>
        <state>BG</state>
        <zip>24128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Fatebenefratelli, U.O. di Oncologia</name>
      <address>
        <city>Benevento</city>
        <state>BN</state>
        <zip>82100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale di Bentivoglio</name>
      <address>
        <city>Bentivoglio</city>
        <state>BO</state>
        <zip>40010</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Bellari, U.O. di Oncologia</name>
      <address>
        <city>Bologna</city>
        <state>BO</state>
        <zip>40139</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale di Budrio</name>
      <address>
        <city>Budrio</city>
        <state>BO</state>
        <zip>40054</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario, Oncologia Medica II</name>
      <address>
        <city>Cagliari</city>
        <state>CA</state>
        <zip>09042</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università Cattolica del Sacro Cuore, Dipartimento di Oncologia</name>
      <address>
        <city>Campobasso</city>
        <state>CB</state>
        <zip>86100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Mariano Santo, U.O. di Oncologia Medica</name>
      <address>
        <city>Cosenza</city>
        <state>CS</state>
        <zip>87100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Cannizzaro, Divisione di Ostetricia e Ginecologia</name>
      <address>
        <city>Catania</city>
        <state>CT</state>
        <zip>95126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Acrispedale Sant'Anna</name>
      <address>
        <city>Ferrara</city>
        <state>FE</state>
        <zip>44100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Pierantoni, Divisione di Oncologia Medica</name>
      <address>
        <city>Forli'</city>
        <state>FO</state>
        <zip>47100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Carlo Poma, Divisione di Oncologia ed Ematologia</name>
      <address>
        <city>Mantova</city>
        <state>MN</state>
        <zip>46100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Ramazzini, Day Hospital Oncologico</name>
      <address>
        <city>Carpi</city>
        <state>MO</state>
        <zip>41012</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario P. Giaccone</name>
      <address>
        <city>Palermo</city>
        <state>PA</state>
        <zip>90100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale M. Ascoli</name>
      <address>
        <city>Palermo</city>
        <state>PA</state>
        <zip>90127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Casa di Cura La Maddalena S.p.A., Dipartimento Oncologico</name>
      <address>
        <city>Palermo</city>
        <state>PA</state>
        <zip>90146</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale S. Massimo, Day Hospital Oncologico</name>
      <address>
        <city>Penne</city>
        <state>PE</state>
        <zip>65017</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro di Riferimento Oncologico, Divisione di Oncolgia Medica C</name>
      <address>
        <city>Aviano</city>
        <state>PN</state>
        <zip>33081</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera S. Maria degli Angeli, Servizio di Oncologia</name>
      <address>
        <city>Pordenone</city>
        <state>PN</state>
        <zip>33170</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile di Faenza, Divisione di Oncologia Medica</name>
      <address>
        <city>Faenza</city>
        <state>RA</state>
        <zip>48018</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Bianchi Melacrino Morelli Ospedale Riuniti, Divisione di Oncologia Medica</name>
      <address>
        <city>Reggio Calabria</city>
        <state>RE</state>
        <zip>89100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale degli Infermi, U.O. Oncologia Medica</name>
      <address>
        <city>Rimini</city>
        <state>RI</state>
        <zip>47900</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile Umberto I, Day Hospital Oncoematologico</name>
      <address>
        <city>Nocera Inferiore</city>
        <state>SA</state>
        <zip>84014</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale S. Chiara, U.O. di Oncologia Medica</name>
      <address>
        <city>Trento</city>
        <state>TN</state>
        <zip>38100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale S. Anna, Day Hospital Oncologico Divisione A</name>
      <address>
        <city>Torino</city>
        <state>TO</state>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale S. Bortolo ULSS 6, U.O. di Oncologia Medica</name>
      <address>
        <city>Vicenza</city>
        <state>VI</state>
        <zip>36100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera D. Cotugno</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale dei Tumori , Divisione di Oncologia Medica B</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale dei Tumori, Divisione di Oncologia Medica C</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Regina Elena, Divisione di Oncologia Medica</name>
      <address>
        <city>Roma</city>
        <zip>00144</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale S. Giovanni Calibita Gatebenefratelli</name>
      <address>
        <city>Roma</city>
        <zip>00186</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHC Maternidade Bissaya-Barreto, Gynecology Unit</name>
      <address>
        <city>Coimbra</city>
        <zip>3000</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istanbul University Medical Oncology</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>Portugal</country>
    <country>Turkey</country>
  </location_countries>
  <reference>
    <citation>Pignata S, Scambia G, Savarese A, Breda E, Scollo P, De Vivo R, Rossi E, Gebbia V, Natale D, Del Gaizo F, Naglieri E, Ferro A, Musso P, D'Arco AM, Sorio R, Pisano C, Di Maio M, Signoriello G, Annunziata A, Perrone F; MITO Investigators. Safety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO-2 randomized trial. BMC Cancer. 2006 Aug 1;6:202.</citation>
    <PMID>16882344</PMID>
  </reference>
  <reference>
    <citation>Pignata S, Scambia G, Savarese A, Breda E, Sorio R, Pisano C, Lorusso D, Cognetti F, Vernaglia Lombardi A, Gebbia V, Scollo P, Morabito A, Signoriello G, Perrone F. Carboplatin and pegylated liposomal doxorubicin for advanced ovarian cancer: preliminary activity results of the MITO-2 phase III trial. Oncology. 2009;76(1):49-54. doi: 10.1159/000178760. Epub 2008 Nov 27.</citation>
    <PMID>19039248</PMID>
  </reference>
  <results_reference>
    <citation>Pignata S, Scambia G, Ferrandina G, Savarese A, Sorio R, Breda E, Gebbia V, Musso P, Frigerio L, Del Medico P, Lombardi AV, Febbraro A, Scollo P, Ferro A, Tamberi S, Brandes A, Ravaioli A, Valerio MR, Aitini E, Natale D, Scaltriti L, Greggi S, Pisano C, Lorusso D, Salutari V, Legge F, Di Maio M, Morabito A, Gallo C, Perrone F. Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial. J Clin Oncol. 2011 Sep 20;29(27):3628-35. doi: 10.1200/JCO.2010.33.8566. Epub 2011 Aug 15.</citation>
    <PMID>21844495</PMID>
  </results_reference>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 15, 2006</study_first_submitted>
  <study_first_submitted_qc>May 15, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 16, 2006</study_first_posted>
  <last_update_submitted>July 14, 2017</last_update_submitted>
  <last_update_submitted_qc>July 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ovarian cancer</keyword>
  <keyword>chemotherapy</keyword>
  <keyword>first-line</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

